madhu-westmeath.blogspot.com
The research deal between the Emeryvillee company and Novato institute formalluended Friday. The money to the Buck disclosed Monday in a Securities and Exchangee Commission filing byNeurobiological Technologies, is the final installment of an upfront payment by Neurobiologicaol Technologies. The institute also receivess a perpetual exclusive worldwide license to the technology developmenft underthe deal. It also will have the sole right to all patentsz underthe agreement. Neurobiologicak Technologies (NASDAQ: NTII) late last year saw its lead the stroketreatment Viprinex, fail a clinical It has since hired an investment bankef to sell the business or its major assets.
As part of the researcb deal, started in November 2007, Buck researcherx tried to create a form of a naturallgyoccurring protein, fibroblast growth factor-2, or FGF-2, that they believe coulcd be at the heart of Huntington’s treatments. Buck scientists foundx that micewith Huntington’s, a fatap hereditary brain disorder, showed a 150 percenft increase in new nerve cells aftetr being treated with FGF-2. Huntington’s affects abougt 30,000 people in the United States andabougt 200,000 Americans are believecd to be at risk of developint the disease. It typically is characterizee by involuntary movementsand dementia, which usuall start to appear in mid-life.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment